MOLBIO
1 call
Concalls & earnings callsMolbio Diagnostics Limited
Every summarised call, newest first. Latest is Q1 FY27, held 8 Sept 2026.
Latest quarter
Q1 FY27 snapshot
Open full brief →Q1 FY27 was led by the Truenat point-of-care molecular platform with recurring kit sales driving revenue, while management pointed to TB scale-up, HPV rollout, and U.S. and Europe expansion as next growth drivers.
| Metric | This quarter | Change | Five-quarter trend |
|---|---|---|---|
| Revenue from operations (Q1 FY27) | ₹408 Cr | — | |
| EBITDA (Q1 FY27) | ₹104 Cr | — | |
| Profit after tax (Q1 FY27) | ₹52.7 Cr | — | |
| Test kits sold (Q1 FY27) | 62.4 lakh kits | — |
Latest guidance
- Grow top line at roughly about 25% for the year with EBITDA of about 24% to 25%, to be tracked on an annual basis
- Continue R&D spend at 5% to 6% of revenue, with bulk for newer platforms and limited capex beyond IPO-funded automation and Bangalore R&D center
- OptraScan not expected to turn profitable in FY ‘27, with meaningful contribution expected from '28 and '29 onwards
Said on the Q1 FY27 call.
Call history
- Q1 FY27Positive tone
Q1 FY27 was led by the Truenat point-of-care molecular platform with recurring kit sales driving revenue, while management pointed to TB scale-up, HPV rollout, and U.S. and Europe expansion as next growth drivers.
- Revenue from operations (Q1 FY27)
- ₹408 Cr
- EBITDA (Q1 FY27)
- ₹104 Cr